The pharmaceutical company Solopharm has secured 8th place in Forbes’ ranking of "20 best pharmaceutical manufacturers in Russia – 2025."
This recognition is the result of the company’s systematic efforts, rapid growth, and strategic focus on developing innovative pharmaceutical production.
The Forbes ranking was compiled based on four criteria: sales in 2024, year-over-year revenue growth, the number of the company’s drug brands in circulation in 2024, and the number of clinical trial approvals granted to the company over the past three years.
Solopharm’s inclusion among the industry leaders confirms its strong market position and significant contribution to the advancement of Russia’s pharmaceutical sector.
Solopharm continues to move forward confidently, maintaining high-quality standards and making effective medicines accessible to millions of consumers.
Company statement: "Solopharm’s inclusion in the Forbes ranking is a credit to our entire team, our partners, and the consumers who trust us. We are not stopping here: production development, innovation, and portfolio expansion remain our strategic priorities. We are confident that Russian pharmaceuticals can be high-tech, modern, and people-centered," commented Solopharm’s press service.
